

Vivesto signs Liberi Group to accelerate partnering activities for Paccal Vet and Cantrixil programs

Solna, Sweden, December 16, 2025 – Vivesto AB, an oncology-focused development company, today announced it has engaged Liberi Group, a global life science consultancy firm based in the Netherlands, to support the company in identifying suitable potential international partners for its lead programs Paccal Vet and Cantrixil.

In November 2025, Vivesto reported positive interim efficacy results from the open label, clinical pilot study with Paccal Vet in dogs with splenic hemangiosarcoma following splenectomy. The company also received positive new preclinical anti-cancer data for Cantrixil in an animal model of Acute Myeloid Leukemia (AML), in which Cantrixil was combined with drugs used in standard-of-care treatments. The recent pipeline advancements and strong data generated to date create attractive partnering opportunities for both programs. Vivesto has therefore engaged Liberi Group to support in identifying suitable international partners, advance partnership discussions, and manage the process leading toward potential strategic collaboration agreements.

"We are pleased to begin working with Liberi Group, whose strong track record in securing high-quality partners for preclinical, clinical, and veterinary projects makes them an ideal fit for Vivesto," said Erik Kinnman, CEO of Vivesto. "Their support across both the Paccal Vet and Cantrixil programs enables us to work cost-effectively and in a coordinated manner as we prepare project materials and initiate targeted outreaches to international partners. This collaboration positions us well ahead of our near-term milestones, including the full results from the Paccal Vet Dog pilot study in Q2 2026, as well as results of the Paccal Vet Cat dose-finding study and Cantrixil PK /toxicology data in the first half of 2026, and strengthens our ability to advance our programs toward their next development stages."

A strategic collaboration with appropriate partners would accelerate and enhance the development and, ultimately, the commercialization of the company's drug candidates by adding capital and capabilities in terms of late-stage development, regulatory affairs, production (CMC) and marketing.

"With the recent progress in Vivesto's lead programs, we believe the company will be in an attractive position for several international players seeking licensing projects in both veterinary and human oncology," said Bram de Jong, Director Business Development at Liberi Group. "We are now working closely with the Vivesto team to prepare suitable presentation- and due-diligence materials, after which we will initiate outreach to suitable potential partners. Our aim is to identify as many interested parties as possible ahead of next year's upcoming milestones."

In the Paccal Vet program, top-line results from the pilot study in dogs are expected in Q2 2026. If positive, the study will be followed by a pivotal clinical trial to further evaluate efficacy and safety, with the goal of achieving full marketing approval. Positive results could also allow for an early conditional approval and market introduction ahead of completion of the pivotal study. The clinical and regulatory pathway will be aligned with a partner, who is also expected to participate in the pivotal study and the commercial manufacturing process.

The Cantrixil program is being prepared for human clinical development, with a PK/toxicology study planned for the first half of 2026. A partner will be required to support the initiation of a clinical Phase 1 study in human AML after 2026, as well as CMC development. Given Cantrixil's unique mechanism of action and promising safety profile, and the strong synergies between the veterinary and human programs, Vivesto recently announced an expansion into a new indication to include cancer-affected dogs, with a pilot study planned to start H2 2026. Continued development in veterinary medicine, including safety evaluation, clinical studies, CMC development and commercial planning, may be carried out jointly with the human program and will also require a strategic partner.

About Liberi Group

Liberi Group is a global life-science consultancy specializing in partnering, licensing and valuation services for biotech and pharmaceutical companies. Leveraging a broad international network of investors, industry partners and strategic players across the US, Europe and Asia, Liberi Group supports clients in out-licensing, co-development partnerships, fundraising, asset valuation and M&A activities. Companies that have engaged Liberi Group include Imugene (Australia), NeoX (China), AGV Discovery (France) and MenoGenix (USA), among others. Their experience-driven and tailored approach helps life-science companies maximize asset value and accelerate commercialization through strategic partnerships.

For More Information:

Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.

Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

Attachments

[Vivesto signs Liberi Group to accelerate partnering activities for Paccal Vet and Cantrixil programs](#)
